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p¼NS for all other covariates). NRM was low in our patient
population (12%), and was not signiﬁcantly different
between HCT-CI groups. Grade 3-4 non-hematologic adverse
events within the ﬁrst 100 days after SCT were signiﬁcantly
more common in the higher HCT-CI groups (P ¼ .02). The
most common adverse events were infectious and gastro-
intestinal. Risk of re-hospitalization within the ﬁrst 100 days
after SCT was not statistically different between groups (17%,
37% and 36% for HCT-CI¼0, 1-2 and 3 respectively, P ¼ .45),
although patients with HCT-CI¼0 did have a trend toward
a lower risk than patients with HCT-CI>0 (17% vs 36%, P¼ .2).
There was no difference in the duration of SCT hospitaliza-
tion between HCT-CI groups.
Conclusion: Despite a high incidence of multiple comor-
bidities (HCT-CI score 3) in our older cohort, HCT-CI
retained its ability to predict OS, speciﬁcally by distinguish-
ing those with HCT-CI 3 as having a particularly poor
prognosis. HCT-CI score 3 was a better predictor of OS than
age or KPS. We conclude that HCT-CI remains a useful
predictor of outcomes in older patients undergoing alloge-
neic SCT.369
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Continuity of care (COC) is acknowledged as a core quality
measure in medicine. There is a little literature known about
the impact of COC on OS after allogeneic hematopoietic stem
cell transplantation Allo-HCT.
Method: Between July 2009 and May 2012, 74 consecutive
Allo-HCT were performed at our center. The patient's clinical
care for the ﬁrst consecutive 41 patients was shared between
the physicians independent of primary transplant physician
(Non- COC). We hypothesized that COC improve OS after
Allo-HCT and the subsequent 33 patients (COC) were fol-
lowed by their transplant physician both as in-patient and
outpatient. Physician's contribution into the care of each
individual patient was calculated from physicians billing
visits. Patient characteristics are shown in table I. Graft vs.
host disease (GVHD) prophylaxis was Calcineurin inhibitor
with MTX/Mycophenolate with the addition of Thymoglo-
bulin for MUD and mismatched RD.
Results: The average contribution of the primary transplant
physician into their patients care during the ﬁrst year post-
transplant was 49% vs. 80% for Non-COC and COC groups
respectively (P¼0.01). There was no difference in patient
characteristics between COC and Non-COC groups except for
older patients in Non-COC. With median duration of follow
up of 815 days for Non-COC and 320 days for COC groups, the
1- year OS was 56% vs. 75% respectively (P¼0.07). Similarly,
there was a trend toward improved DFS for COC (1-year DFS
of 68% vs. 48%, P¼0.11). Both cumulative incidence of relapse
and treatment related mortality (TRM) at 1-year were lower
in COC compared to Non-COC groups; 9% vs. 25% and 17% vs.
25% respectively. The cumulative incidence of grade II eIV
acute GVHD was 64% for Non-COC vs. 46% COC respectively.
There was more patients with grade III/IV aGVHD; 13/41
(32%) in Non-COC compared to 6/33(18%) in COC, however
this difference was not statistically signiﬁcant (p¼0.27).Additionally, there was no difference in OS in patients with
grade III/IV aGVHD in Non-COC (13 patients) vs. COC (6
patients), P¼0.85. In contrast, Patients without grade III/IV
aGVHD had a statistical OS advantage in favor of COC (27
patients) vs. Non-COC (28 patients) with one year OS of 90%
vs. 68% respectively, P¼0.05. Cumulative incidence of chronic
GVHD at one year was 77% for COC and 48% for Non-COC
patients, P¼0.02.
Conclusion: Continuity of care may favorably improve OS
after Allo-HCT. COC did not improve OS in patients with
severe aGVHD but may result in OS advantage in patients
with grade II aGVHD. Personnel knowledge of the patients
and promptness in initiating GVHD therapy in COC group
may have contributed to the improved OS in patients with
grade II aGVHD. Similarly, the more intense immune
suppression for patients with severe GVHD in NCOC
group may have contributed to higher relapse and TRM
observed.370
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With the growing diversity in race and ethnicity of the
American population, there is a need to characterize the
disparities in access and outcomes of hematopoietic cell
transplantation (HCT) for the racial and ethnic minorities.
This single center study examined the association of
ethnicity/ race with outcomes after HCT. Clinical information
of 301 adult patients who underwent single allogeneic HCT
for a hematological disorder at Mayo Clinic in Arizona from
11/03 to 06/12 was obtained from the institutional database
and retrospective chart review. Information about ethnicity
was self-reported by patients. Median follow-up was 20
months (range 3-106 months). Overall survival was
compared between the racial/ ethnic groups using Cox
regression while adjusting for other clinical factors.
The study included 224 white patients (75%) and 77
ethnic minority patients (25%). Non-whites/ Hispanics were
younger at HCT (median age 40 vs. 56, P ¼ .001). Use of
myeloablative conditioning (61% vs. 31%, P < .001) and
related donors (50% vs. 35%, P ¼ .01) was more common in
Non-whites/ Hispanics. There were no differences in disease
diagnosis and risk, gender distribution and HCT- comorbidity
index between the two groups. More Non-whites/Hispanics
were unemployed (51% vs. 25%; P < .001). No statistically
signiﬁcant differences in the incidence of post-transplant
complications including infections, veno-occlusive disease,
grade II-IV acute and NIH chronic GVHD were seen between
the two groups. Cumulative incidence of relapse at 5 years
was higher in Non-whites/ Hispanics (33% vs. 22%; P ¼ .03).
Though the univariate analysis showed no differences in
overall survival (5 year OS: 52% for Whites vs. 50% for Non-
whites/Hispanics; P ¼ .44), a higher risk for mortality was
seen in the multivariate analysis for ethnic minorities as
compared to the white patients. (Table)
Table
Multivariate analysis for overall survival after HCT
Variable Hazard ratio 95% CI P value
Race Ethnicity
White 1.0
Non-white/ Hispanic 1.72 1.03 to 2.87 0.04
Age
<50 1.0
 50 1.60 0.95 to 2.70 0.07
Disease
Lymphoma 1.0
Leukemia/ MDS 1.18 0.58 to 2.42 0.64
Others 1.36 0.42 to 4.41 0.6
Disease risk
Low 1.0
Intermediate 1.24 0.66 to 2.35 0.5
High 2.36 1.39 to 4.00 0.001
Donor
Related 1.0
Unrelated 1.45 0.94 to 2.22 0.08
Conditioning
Reduced intensity 1.0
Myeloablative 1.39 0.85 to 2.3 0.19
Karnofsky performance score
100 1.0
<100 2.92 1.82 to 4.69 < .001
HCT-CI score 1.08 0.97 to 1.19 0.13
CMV status
D-/R- 1.0
Others 1.5 0.85 to 2.64 0.16
Employment status
Employed 1.0
Unemployed 1.03 0.63 to 1.69 0.9
Retired 1.44 0.84 to 2.48 0.18
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underscores the need for better understanding of the factors
responsible for differential outcomes and continued efforts
to eliminate disparities in access and outcomes of HCT.
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Outcome of Second Transplants in Pediatric Patients with
Hematological Malignancies After a Hematopoietic Stem
Cell Transplant (HSCT) From a Different Donor.
Assessment of Chimerism by Real -Time PCR to
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A retrospective analysis of 13 patients (9males, 4 females)
aged 1-16 (median, 9) years were transplanted at Lurie
Children's between 2002 to 2011 (AML n¼ 2, ALL n¼11).
Donor sources for the 1st HSCT were 8 match related sibling
(MRS) and 5 unrelated (2/5 cord blood) and for the 2nd HSCT
were 5 MRS and 8 unrelated. Two conditioning regimens; A:
fractionated TBI 1200cGy in 150cGy fractions from day -7 to
-4, Etoposide 1000 mg/m2 from day -3 and Cyclophospha-
mide 60 mg/Kg day -3 to day -1, 1st HSCT (n¼7) and 2nd HSCT
(n¼6), B: Fludarabine 30 mg/m2/day from day -10 to -6,
Busulfan (dose based on PK of the test dose to achieve an AUC
4000microM-min/day) day -5, -4 and ATG (rabbit ATG) 2mg/
kg from day -4 to -9, 1st HSCT (n¼3) and 2nd HSCT (n¼10).
GVHD prophylaxis was regimen speciﬁc for regimen A (CSA/
Tacro, short course MTX  ATG) and regimen B (CSA/Tacro,
MMF ECP). Chimerism was evaluated by real-time PCR
(Applied Biosystems 7500) using AlleleSEQR (Cellera),
weekly after the second week, full donor chimerism (FDC)
was deﬁned as >98%  1%. Median time from diagnosis to1st HSCT was 202 days. The median time from the 1st to the
2nd HSCT was 531 days. ANC > 500 /mL was achieved at
a median of 15 (10-39) days in the 1st, compared to 18.5 (10-
25) days after the 2nd (P ¼ .7). Un-sustained platelet count
>20.0/ mL was attained at amedian of 16.5 (1-54) days and 19
(0-54) days at 1st and 2nd (P ¼ .8), respectively. FDC was
achieved at a median of 34.5 (12-63) days in 13/13 after the
1st and a median of 44 (22-108) days in 10/13 after the 2nd.
The median follow-up after the 2nd HSCT was 1259 (35-
3508) days. The Kaplan- Meier estimates of survival at 3 and
5 years were 69.2% and 43.3%, respectively (median follow up
of 1735 days). Seven patients (1 with partial chimerism, 6
with FDC) are alive after the 2nd HSCT, free of disease with
a median follow up of 1562 (range 915-3508) days. Six
patients have expired, three of cGVHD complications in
remission (3 with FDC) and three patients expired from
progressive leukemia (2 with partial chimerism). Patients
who relapse after the 1st myeloablative HSCT can be
successfully treated with a 2nd HSCT from a different donor.
Patients who did not achieve a FDC after the 2nd transplant
were at a higher risk of relapse. One patient with partial
chimerism has remained in CR after developing graft failure
after the 2nd HSCT, but achieving FDC from the ﬁrst donor.
Patients who developed cGVHD after the 2nd transplant with
a FDC did not relapse but died of cGVHD complications in
remission. All but one of the surviving patients has cGVHD.
Chimerism analysis is the index for which the risk of relapse
is determined. Larger number of patients will be needed to
conﬁrm these preliminary observations.372
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Background: Although allogeneic hematopoietic stem cell
transplantation (HSCT) has beenwidely performed for severe
aplastic anemia (SAA), the standard conditioning regimen
has yet to be established. Recently, the outcomes of a variety
of reduced-intensity conditioning regimens using ﬂudar-
abine have been reported.
Aims: We have retrospectively evaluated the safety and
efﬁcacy of allogeneic HSCT for SAA using ﬂudarabine,
reduced-dose cyclophosphamide, and ATG.
Patients & Methods: Six patients (median age 30 (range:
22-61)) with SAA who underwent allogeneic bone marrow
transplantation from an HLA-identical sibling (n¼3) or an
HLA-matched unrelated donor (n¼3) were evaluated.
Conditioning included ﬂudarabine (120 mg/m2), cyclop-
hosphamide (100 mg/kg), and ATG (Thymoglobulin;
3.75 mg/kg). In addition, 2 Gy of TBI (with ovarian shielding
for young female patients) was delivered for heavily trans-
fused patients or HSCT from an unrelated donor. For the
prophylaxis of graft-versus-host disease (GVHD), cyclo-
sporine A or tacrolimus with short-term methotrexate was
given.
Results: The transplant procedure was generally well-toler-
ated and there were no life-threatening complications. All
patients achieved neutrophil and platelet engraftment and
became transfusion independent. Full donor chimerism was
conﬁrmed on whole bone marrow cells at day 28 after
transplantation. Only one patient developed acute GVHD
(grade II) and none developed chronic GVHD. With a median
follow-up period of 15.9 months (range: 11.6-22.4 months),
